Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Non Operating Income: 2009-2025

Historic Non Operating Income for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$23,337.

  • China Pharma Holdings' Non Operating Income rose 28.53% to -$23,337 in Q3 2025 from the same period last year, while for Sep 2025 it was $45,066, marking a year-over-year increase of 127.01%. This contributed to the annual value of -$147,499 for FY2024, which is 54.89% up from last year.
  • Latest data reveals that China Pharma Holdings reported Non Operating Income of -$23,337 as of Q3 2025, which was down 118.86% from $123,753 recorded in Q2 2025.
  • China Pharma Holdings' Non Operating Income's 5-year high stood at $123,753 during Q2 2025, with a 5-year trough of -$332,029 in Q4 2021.
  • Its 3-year average for Non Operating Income is -$36,458, with a median of -$39,840 in 2024.
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 208.77% in 2021, then soared by 365.51% in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Non Operating Income stood at -$332,029 in 2021, then skyrocketed by 71.34% to -$95,172 in 2022, then skyrocketed by 49.86% to -$47,722 in 2023, then surged by 40.50% to -$28,396 in 2024, then grew by 28.53% to -$23,337 in 2025.
  • Its Non Operating Income was -$23,337 in Q3 2025, compared to $123,753 in Q2 2025 and -$26,954 in Q1 2025.